Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	41.87B
Revenue (ttm)	7.95B
Net Income (ttm)	1.83B
Shares Out	6.60B
EPS (ttm)	0.28
PE Ratio	23.05
Forward PE	17.14
Dividend	0.03 (0.48%)
Ex-Dividend Date	Jul 14, 2025

Volume	30,317,012
Average Volume	25,355,336
Open	6.36
Previous Close	6.34
Day's Range	6.33 - 6.42
52-Week Range	6.23 - 7.30
Beta	0.46
RSI	34.87
Earnings Date	Mar 27, 2026

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The company was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2024, SHE:002252's revenue was 8.18 billion, an increase of 2.67% compared to the previous year's 7.96 billion. Earnings were 2.19 billion, an increase of 23.25%.